CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion

Publikation

CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion

Wissenschaftlicher Artikel/Review - 20.08.2018

Preusser Matthias, De Mattos-Arruda Leticia, Thill Marc, Criscitiello Carmen, Bartsch Rupert, Ruhstaller Thomas, de Azambuja Evandro, Zielinski Christoph C

Zitation

Preusser M, De Mattos-Arruda L, Thill M, Criscitiello C, Bartsch R, Ruhstaller T, de Azambuja E, Zielinski C. CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion. ESMO Open 2018; 3:e000368.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

ESMO Open 2018; 3

Veröffentlichungsdatum

20.08.2018

ISSN (Druck)

2059-7029

Seiten

e000368

Kurzbeschreibung/Zielsetzung

This article is the result of a round-table discussion organised by ESMO Open in Vienna in December 2017. Its purpose is to discuss the background and advances in the evidence regarding cyclin-dependent kinase 4/6 inhibitors (palbociclib, ribociclib and abemaciclib) in the treatment of metastatic and early-stage breast cancer and to explore what the key open research questions are and next steps should be.